BOOK BY FRIDAY 29TH MARCH & SAVE UP TO €500

21st-23rd May 2019 | Paris, France

www.ndd-europe.com

NDD

Neurodegenerative Drug Development Europe

Overcome Translational Challenges Preventing the Development of Clinically Effective Neurodegenerative Therapeutics

Expert Speakers Including:

Hugh Marston
Senior Research Fellow & Head of Translational Neuroscience
Eli Lilly

Ross Jeggo
Head of Research, Neuropsychiatry Center for Therapeutic Innovation
Servier

Jan Torleif Pedersen
Director, Therapeutic Biology Lead, Alzheimer's Disease & Dementia, Neuroscience
Lundbeck

Angel Cedazo-Minguez
Head of Neuroscience Research
Sanofi

Alastair D. Reith
Senior Director, External Innovation
GSK

Andy Takle
Executive Director & Head, Hatfield Research Laboratories, Neurology Business Group
Eisai

Innovation Partner:

AXOL Quality Cells, Consistent Results

Event Partner:

Ncardia Stem cell experts

CRF HEALTH Bracket A CRF BRACKET COMPANY

Tel: +44 (0)20 3141 8700 **Mail:** info@hansonwade.com

The Neurodegenerative Disease Forum

hansonwade

NDD Europe for Neurodegenerative Drug Development

Attend NDD Europe to improve your knowledge of the latest neurodegeneration biomarker innovations available, discover novel animal models and establish the precompetitve connections enabling you to successfully advance to the clinic and optimize patient stratification.

Designed alongside neurodegeneration experts from **Sanofi, AbbVie, Roche, Eli Lilly** and **Janssen**, **NDD Europe** will share the field's cutting edge scientific advances enabling you to translate your neurodegenerative research into a clinically effective therapeutic for neurodegenerative diseases.

NDD Europe will allow you to:

- Discuss and learn about the cutting edge advances in neurodegenerative biomarkers to progress translation and patient stratification
- Discover advances in preclinical models and strategies improving predictability of clinical performance
- Participate in forward thinking debates and discussions crucial for refreshing neurodegenerative approaches and encouraging precompetitive collaboration

With 70+ thought-leaders meeting in Paris at **NDD Europe**, this will be an unrivalled opportunity for you to gain the latest scientific insights, have your peers review your research and grow your collaborator network.

What our attendees have said about our meetings

"Great meeting that has the right balance of science, drug discovery & development and networking"

Jonathan Levenson, Senior Director at Proclara BioSciences

"Outstanding conference"

Richard Wyse, Director of R&D at The Cure Parkinson's Trust

Join NDD Europe to:

1. Familiarise yourself with the latest preclinical models of neuro-degenerations and **identify the most promising strategies to predict clinical efficacy**



2. Discover the latest technology innovations **improving blood-based biomarker diagnostics and patient stratification to allow clinical success**

3. Grow your awareness of the precompetitive strategies **advancing neuro-degenerative drug development through shared knowledge, experience and data**

4. Share the success of your neuro-degenerative research at the Poster Session with your peers to **receive constructive feedback and spark conversation with potential collaborators**



5. Evaluate the current therapeutic approaches targeting neuro-degeneration **to guide your future target selection and validation**

Tel: +44 (0)20 3141 8700 Mail: info@hansonwade.com
www.ndd-europe.com The Neurodegenerative Disease Forum
hansonwade

Your Expert Speakers

Angel Cedazo-Minguez
Head of Neuroscience Research
Sanofi

Alan Griffith
MSAT Lead & BSO
MeiraGTx

Alastair D. Reith
Senior Director, External Innovation
GSK

Andy Takle
Executive Director & Head, Hatfield Research Laboratories, Neurology Business Group
Eisai

Carol Routledge
Director of Research
Alzheimer's Research UK

Daniel Rock
Microglia Application Specialist
Axol Bioscience

Jo Jackson
Senior Research Scientist
Eli Lilly

Hugh Marston
Senior Research Fellow & Head of Translational Neuroscience
Eli Lilly

Jan Egebjerg Jensen
Senior Director, Neurodegeneration Discovery Biology
Janssen

Jan Torleif Pedersen
Director, Therapeutic Biology Lead, Alzheimer's Disease & Dementia, Neuroscience
Lundbeck

Luc Ver Donck
Scientific Director, Head of Alzheimer Disease Animal Models, Neuroscience Discovery
Janssen

Mark Schmidt
Senior Director
Janssen

Nathalie Cartier-Lacave
Acting Chief Scientific Officer
BrainVectis

Patrick Downey
Director, Head of Neurodegeneration
UCB

Ralph Laufer
Chief Scientific Officer
Lysogene

Richard Wyse
Global Director of Research and Development
The Cure Parkinson's Trust

Ross Jeggo
Head of Research, Neuropsychiatry Center for Therapeutic Innovation
Servier

Tania Nikolcheva
Principal Medical Director
Roche

Tauseef Butt
Chief Executive Officer
Progenra

Ulf Andreasson
Associate Professor
University of Gothenburg

Pre-Conference Workshops Tuesday 21st May

Workshop A

Seeking Blood-Based Biomarkers of Neurodegeneration

10:00am – 1:00pm

One of the main challenges preventing the successful development of neurodegenerative therapeutics is the lack of translatable biomarkers available. Efficient and successful blood-based biomarkers would transform the drug development field, from preclinical model studies to patient diagnosis.

Attend this workshop to:

- Discover the blood-based biomarker technologies available
- Discuss the need for robust blood-based biomarkers of neurodegeneration
- Assess precision and fluctuation limitations of biomarker detection
- Introduce blood-based biomarkers to clinical studies

Workshop Leader

Ulf Andreasson
Associate Professor
University of Gothenburg

Workshop B

Evaluating Gene Therapy as a Therapeutic for Neurodegeneration

2:00pm – 5:00pm

Gene therapy has made important advances in the clinic over the last decade. Among neurological diseases, severe genetic neurodegenerative conditions have been the focus of initial clinical applications. Gene therapy has also addressed complex neurodegenerative diseases, particularly Parkinson's disease, with encouraging results in human patients. It demonstrates that specific targeting of central nervous system cells is a relevant strategy for severe pathologies and that efficient access to the CNS with viral vectors is an achievable goal.

Attend this workshop to:

- Evaluate the gene therapy clinical applications that have been utilised for neurodegenerative diseases
- Discuss the limitations and challenges faced by gene therapy developers to obtain and demonstrate benefit in patients
- Review the latest developments that could allow new clinical applications with high beneficial potential

Workshop Leader

Nathalie Cartier-Lacave
Acting Chief Scientific Officer
BrainVectis

Conference Day One
Wednesday 22nd May

Ross Jeggo
Head of Research, Neuropsychiatry Center for Therapeutic Innovation
Servier

8.00 **Chair's Opening Remarks**

The Future for Neurodegenerative Drug Development

Richard Wyse
Global Director of Research and Development
The Cure Parkinson's Trust

8.15 **Reviewing Past Failures & Challenging Traditional Thinking to Guide Future Research**

- Evaluating why many promising preclinical candidates have failed in neuroprotective clinical trials
- Discussing the lack of effective biochemical & imaging biomarkers, relatively poor clinical evaluation scales, and limited understanding of patient subgroups
- Presenting a brighter future, both in conventional and regenerative approaches
- Reviewing multiple recent breakthroughs in genetics, patient stratification, wearables, AI, and some evolving new clinical successes, now mean that many diverse and promising therapeutic targets will be studied in upcoming clinical trials

Ross Jeggo
Head of Research, Neuropsychiatry Center for Therapeutic Innovation
Servier

8.45 **Moving Forward: The Changing Landscape of Neurodegenerative Drug Discovery & Development**

- Evaluating what ingredients are needed for successful R&D in neurodegenerative disease?
- Is it possible to build a feasible drug discovery portfolio in neurodegenerative disease in 2019?
- Predicting the future is not possible. What can we do to model 2025 and beyond?

9.15 **Panel Discussion: Future Thinking for Neurodegenerative Disease Drug Development**

- Reviewing the past failures in the neurodegenerative field
- Evaluating the potential for neurodegenerative drug development
- Discussing the lessons learned and future opportunities
- Encouraging productive and precompetitive behaviours

Ross Jeggo
Head of Research, Neuropsychiatry Center for Therapeutic Innovation
Servier



Richard Wyse
Global Director of Research and Development
The Cure Parkinson's Trust

Jan Torleif Pedersen
Director, Therapeutic Biology Lead, Alzheimer's Disease & Dementia, Neuroscience
Lundbeck

9.45 **Speed Networking**

This session is the ideal opportunity to meet face-to-face with the key thought leaders working in the CNS field. Specifically designed to connect you with new contacts from the most active companies in the field, the renowned Speed Networking session will be one of the most valuable hours you will spend at NDD Europe.

10.30 **Morning Refreshments**

Seeking Robust Biomarkers of Neurodegeneration & Strategies to Improve Their Translatability

Jan Torleif Pedersen
Director, Therapeutic Biology Lead, Alzheimer's Disease & Dementia, Neuroscience
Lundbeck

11.00 **Linking CSF-Tau Biomarker Changes to Neuropathological Changes in Alzheimer's Disease**

- Reviewing hyperphosphorylated tau, a key pathological species in Alzheimer's disease
- Targeting this species in preclinical models prevents the seeding and spreading of tau pathology
- Identification of c-terminal tau assays has been a key roadblock in moving tau therapies forward. Here, we present the development of such assays and their evaluation in human and animal samples

Mark Schmidt
Senior Director
Janssen

11.30 PET Imaging Methods for Intervention Trials in Alzheimer's Disease: Promises & Pitfalls

- PET imaging in AD trials: applying the ATN System
- Reviewing quantitative amyloid PET imaging: strengths and limitations
- Tau PET imaging: where do we stand?
- Assessing functional PET imaging as a marker of neurodegeneration
- Reviewing intervention trials as collaborative research: AMYPAD and EPAD

12.00 Roundtable Discussion: Discussing Current Biomarkers of Neurodegeneration & the Advances & Strategies Needed for Future Success in Patient Stratification, Diagnosis & Treatment

- With the success of neurodegenerative therapeutics relying on the translatability of biomarkers, this discussion will enable you to share your opinions on this topic, including:

1. **Reviewing current biomarkers: What current biomarkers are showing promise?**

2. **What biomarker innovations are becoming available?**

12.30 Lunch & Networking

Encouraging Precompetitive Strategies, Collaborations & Consortia to Advance the Neurodegenerative Field

Andy Takle
Executive Director & Head, Hatfield Research Laboratories, Neurology Business Group
Eisai

2.00 Meeting the Challenges of Neuroscience Drug Discovery Through Open Innovation Collaborations

- Creating outcome focused, win-win collaborations with academic partners
- Adapting to the needs of collaborative partners
- The Therapeutic Innovation Group; a novel collaborative model

Jan Egebjerg Jensen
Senior Director, Neurodegeneration Discovery Biology
Janssen

2.30 IMI for Neurodegenerative Disorders: A Public-Private Partnership to Accelerate Drug Discovery

- Discussing how precompetitive strategies can enable drug discovery
- Identifying collaborations to advance drug discovery from disease biology on novel target to clinical trial analysis and cohorts
- Reviewing the success of various IMI projects

3.00 Afternoon Refreshments & Networking

Alastair D. Reith
Senior Director, External Innovation
GSK

3.30 LRRK2: Integrating Collaborative Breakthrough Science with Drug Discovery & Development

- Leucine rich repeat kinase 2 (LRRK2) is a leading example of how clinical genetic based drug target identification is stimulating a precision medicine-based approach to discovery of disease modifying medicines for people with Parkinson's
- Sustained collaborative efforts across academic, charitable and commercial sectors to expedite progress on scientific knowledge
- How this precompetitive collaborative work has been of fundamental value in translational efforts to identify LRRK2 modulators, evaluate on-target liability risks and enable biomarker assay development & clinical trial design

4.00 Panel Discussion: Precompetitive Strategies to Strengthen Neurodegenerative Research

- Understanding the importance of sharing experiences and pooling data
- Improving the reproducibility of studies amongst different research groups
- Discussing alternative funding strategies

Carol Routledge
Director of Research
Alzheimer's Research UK

Alastair D. Reith
Senior Director, External Innovation
GSK

Andy Takle
Executive Director & Head, Hatfield Research Laboratories, Neurology Business Group
Eisai

Hugh Marston
Senior Research Fellow & Head of Translational Neuroscience
Eli Lilly

4.30 Chair's Closing Remarks



4.45 Scientific Poster Session

The learning at networking continues at the Poster Session, an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new, beneficial relationships. You will have the opportunity to present and review presentations displaying new data from neurodegenerative disease research, such as novel therapeutic targets and advances in clinical development.

"I was impressed by many of the speakers and learnt a significant amount, which I was able to bring back to our discovery team"

Eisai

"A great meeting. The networking opportunities were fantastic"

Pfizer

19 Expert Speakers

7+ Hours of Networking

2 Workshops

3 Panel Discussions

Tel: +44 (0)20 3141 8700 Mail: info@hansonwade.com
www.ndd-europe.com The Neurodegenerative Disease Forum

Conference Day Two
Thursday 23rd May

Ross Jeggo Head of Research, Neuropsychiatry Center for Therapeutic Innovation **Servier**	**8.15**	**Chair's Opening Remarks**

Exploring Preclinical Models of Neurodegeneration to Improve Clinical Efficacy Predictions

Luc Ver Donck Scientific Director, Head of Alzheimer Disease Animal Models, Neuroscience Discovery **Janssen**	**8.30**	**Neurodegeneration: Novel Animal Models of Alzheimer's Disease** • Genetic animal models are diverse and serve various purposes • These models have translational value within the biochemical process that is impacted, but do not reflect the full human disease phenotype • Understanding that overexpression of mutated gene is often a confounding factor • Exploring new animal models hold promise for improved translational value
Daniel Rock Microglia Application Specialist **Axol Bioscience**	**9.00**	**Molecular & Functional Characterisation of IPSC-Derived Microglia: Developing Tools to Model Neurodegeneration** • Developing a scalable and reproducible generation of physiologically-relevant microglia • Validation of robust, disease-relevant assays • Building a translatable neurodegeneration model: longitudinal monitoring of healthy and patient donor iPSC co-cultures • Assessing the contribution of astrocytes and microglia to the neuroinflammatory microenvironment
Jo Jackson Senior Research Scientist **Eli Lilly**	**9.30**	**Reverse Translation in Practice: Gaining More Valuable Information from Animals Models in Neurodegenerative Drug Discovery** • Neurodegenerative drug discovery efforts have faced significant challenge from a recent series of late-stage failures. Promising preclinical data has not been recapitulated in the clinic • Animal models should be more carefully aligned with human disease characteristics and outcomes • Bridging the translational gap by greater use of physiological correlates to map drug effects on brain activity between humans and rodents • An overview of recent advances in strategies and concepts of reverse translation
	10.00	**Morning Refreshments & Networking**

Assessing Current Methods of Validation of Neurodegenerative Targets

Patrick Downey Director, Head of Neurodegeneration **UCB**	**11.00**	**Epitope Determines Efficacy of Therapeutic Anti-Tau Antibodies in a Functional Assay with Human Alzheimer Tau** • Growing evidence suggest that tau misfolds and may propagate pathology by spreading from cell to cell in a 'prion like' manner • Blocking the spread of extracellular seeds with an antibody may therefore be a viable therapeutic approach • We developed a robust and quantitative cell based assay and employed an unbiased screening approach to identify the antibody with the highest activity against human tau seeds isolated from AD and PSP patients • We found that an antibody targeting the mid-region of Tau was more efficacious than N-terminal antibodies in this assay and our data highlights the difficulty of predicting antibody accessible epitopes on pathological tau seeds
Angel Cedazo-Minguez Head of Neuroscience Research **Sanofi**	**11.30**	**The Need for Strategical Changes in Alzheimer's Disease Research** • Understanding the biology behind AD • Discussing the current biomarkers of neurodegeneration and future opportunities • Accounting for disease heterogeneity • Reviewing the lessons learned from the last decade
	12.00	**Lunch & Networking**

Assessing Therapeutic Approaches Targeting Neurodegeneration

Ralph Laufer
Chief Scientific Officer
Lysogene

1.00 Gene therapy for a neurodegenerative lysosomal storage disease by direct to brain delivery of a recombinant AAV vector

- Reviewing the challenges of gene therapy for CNS diseases
- Assessing the delivery of AAV vectors to the CNS
- Proving preclinical proof of concept using disease models
- Evaluating the translation of gene therapy therapeutics to the clinic

Tauseef Butt
Chief Executive Officer
Progenra

1.30 Creating Healthy Dopaminergic Neurons by Novel Approaches to Parkin Modulators

- Current treatments for Parkinson's disease cannot prevent dopaminergic neuron destruction or treat the underlying causes of neurodegeneration
- Human genetics and biochemical data indicate that dysfunction in the ubiquitin proteasome system is the cause of PD/AD and damaged mitochondria accumulate and contribute to neuronal death
- The ubiquitin ligase Parkin eliminates damaged mitochondria and preserves neuronal health. Small molecule Parkin modulators could be developed into drugs that can treat PD
- Identifying modulators of Parkin that restore damaged mitochondria and build new mitochondria
- Presenting a pharmacological profile of these compounds, including their mechanism of action and effects on PD and AD models

Alan Griffith
MSAT Lead & BSO
MeiraGTx

2.00 From Ocular to Neurodegenerative Disease: How to Deal with the Demands of Commercial Gene Therapy Products

- Establishing robust and scalable potency assays early in development to support IMPD submissions
- Investigating novel manufacturing and preclinical technologies to ensure continuous improvement
- Understanding the role of automation in gene therapy manufacturing and QC
- Key Gaps in future development of large indications

2.30 Afternoon Networking & Refreshments

Utilising Biomarker Strategies to Improve Patient Stratification for Clinical Trials

Tania Nikolcheva
Principal Medical Director
Roche

3.00 Identification of Biomarkers for Early Detection of Neurodegenerative Phenotypes: Application to Clinical Development

- Highlighting the pre-symptomatic period of neurodegenerative diseases where characteristic neuropathological changes are already detectable
- Identifying individuals at an early stage of the disease with biomarkers of the underlying pathology (fluid, imaging, genetic, digital) when potential disease modifying therapies may have a better chance of success
- Over the last decade such biomarkers were successfully developed in the field of Alzheimer's Disease; they became integral part of AD research diagnostic criteria, and are commonly in use in clinical trials
- Discussing the application of such approaches to clinical development in other neurodegenerative diseases

Hugh Marston
Senior Research Fellow & Head of Translational Neuroscience
Eli Lilly

3.30 Improving Stratification in Neurodegenerative Disease Using Imaging & Other Endpoints

- Identifying the right patient for the right drug, study or trial is vital, therefore improving our ability to accurately stratify in complex disorders is key
- Introducing improved imaging agents and techniques which are offering fascinating insights into these disorders and hence improved stratification
- Combining different modalities and other endpoints can further enhance this process as preliminary data from the IMI PRISM project will illustrate

4.00 Panel Discussion: Optimising Clinical Studies: Valid Biomarkers & Patient Stratification

- How best to identify the correct patient populations using early biomarkers of neurodegenerative disease
- Strategies for patient recruitment

Richard Wyse
Global Director of Research and Development
The Cure Parkinson's Trust

Hugh Marston
Senior Research Fellow & Head of Translational Neuroscience
Eli Lilly

Tania Nikolcheva
Principal Medical Director
Roche

4.30 Chair's Closing Remarks

Partnership Opportunities

WHY PARTNER

Neurodegeneration experts from **AbbVie, Sanofi, Lundbeck** and **Janssen**, along with other leading drug developers, are actively seeking partners to help them succeed in the clinic.

With 70+ CNS R&D decision makers attending **NDD Europe**, this meeting will give you the perfect opportunity to:

- Showcase your high quality services and novel technology innovations
- Network with the field's leading drug developers to build rapport and create valuable relationships
- Learn about the field's current opinions of service providers and showcase your neurodegeneration expertise and establish your credibility as a high quality research partner

To find out more about sponsorship opportunities and how we can support you to make and sustain valuable partnerships with the leading neurodegenerative drug developers, please get in touch:

Sponsor@hansonwade.com

AUDIENCE SENIORITY



- **C-Level: 20%**
- **President/VP: 20%**
- **Global Head/Head of: 15%**
- **Director: 25%**
- **Principal Scientist/ Scientist: 15%**
- **Professor: 5%**

2019 PARTNERS

AXOL
Quality Cells, Consistent Results

Innovation Partner

AXOL's hiPSC-derived Microglia provide a reproducible, physiologically-relevant model in an easy-to-use, assay-ready format for investigating neuroglia involvement in neurodegeneration and neurodevelopment. This homogenous and reproducible population of iPSC-derived Microglia exhibit physiologically relevant functionality, are highly phagocytic and produce cytokines in response to pathogens. They also express the microglia-specific marker TMEM119 along with myeloid markers TREM2 and IBA-1, making these iPSC-derived Microglia suitable models for investigating neuroinflammation in Alzheimer's disease, multiple sclerosis and Parkinson's disease.

www.axolbio.com

Ncardia
Stem cell experts

Event Partner

Ncardia believes that stem cell technology will help give patients faster access to better and safer medicines by improving the drug discovery and development process. The company develops and produces highly predictive human cellular assay systems for safety and efficacy testing of drug candidates. Ncardia is based in Belgium, the Netherlands, Germany and the USA. The company is privately held and established following the merger of Pluriomics and Axiogenesis.

www.ncardia.com/discoverhit

CRF HEALTH Bracket
A CRF BRACKET COMPANY

Event Partner

CRF Bracket provides life science companies with patient-centric technology for clinical research including electronic clinical outcome assessments (eCOAs), eConsent, patient engagement, interactive response technology (IRT), clinical supply forecasting and management, and endpoint quality analytics and services. In 20 years the company has delivered solutions to over 4,000 global clinical trials.

www.bracketglobal.com

GET INVOLVED

Okeefe Ogholo
Business Development Manager
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

Ready to Register?

3 EASY WAYS TO BOOK

www.ndd-europe.com/take-part/register

Tel: +44 (0)20 3141 8700

Email: register@hansonwade.com

1. Network with the field's thought leaders to share, learn and collaborate
2. Widen your knowledge of the cutting edge scientific innovations and strategies available to help advance your neurodegenerative research
3. Discuss and debate the field's most pressing challenges and be part of the conversations transforming the field

Team Discounts*

- **2-3 delegates: 10% discount**
- **4+ delegates: 20% discount**

Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.
Contact: register@hansonwade.com

SECURE YOUR PLACE

Standard Pricing	Register & Pay Before Friday, 29th March	Standard Prices
GOLD Conference + 2 Workshops	€2797 **(Save €500)**	€3097 **(Save €200)**
SILVER Conference + 1 Workshop	€2398 **(Save €400)**	€2698 **(Save €100)**
BRONZE Conference Only	€1999 **(Save €300)**	€2299
Workshops (Each)	€499	

Small Biotech Pricing*	Register & Pay Before Friday, 29th March	Standard Prices
GOLD Conference + 2 Workshops	€1397 **(Save €600)**	€1697 **(Save €300)**
SILVER Conference + 1 Workshop	€1298 **(Save €450)**	€1598 **(Save €150)**
BRONZE Conference Only	€1199 **(Save €300)**	€1499
Workshops (Each)	€249	

*T&Cs Apply: A small biotech discounted rate is available to allow newer, less established companies to attend this meeting. Model and service providers are excluded and all bookings at this rate are subject to organiser approval. Email info@hansonwade.com to enquire about the rate or apply.
**The small biotech rate is also applicable to academics, please also email info@hansonwade.com so we can assist you further.
*** All Prices subject to 20% VAT

VENUE

Hilton Paris La Defense
2 Place De La Defense CNIT
BP 210, Paris, 92053, France

For further information or assistance, please visit www3.hilton.com/en/hotels/france/hilton-paris-la-defense-PARLDHI